Tissue distribution and metabolism of γ-linolenoyl-3-eicosapentaenoyl propane diol enterally or intravenously administered to mice bearing human pancreatic carcinomas

Anticancer Research

Volumn 19, Issue 3 A, 1999, Pages 2041-2048

  De Antueno, Roberto ^a   Bai, M ^a   Elliot, M ^a  

^a Scotia Research Institute   (Canada)

Author keywords

AsPC 1; Diol lipids; Eicosapentaenoic acid; Galactolipids; Gammalinolenic acid; Pancreatic carcinoma

Indexed keywords

ARACHIDONIC ACID; GAMMA LINOLENOYL 3 EICOSAPENTAENOYL PROPANE DIOL; ICOSAPENTAENOIC ACID; LINOLENIC ACID; LIPID; POLYUNSATURATED FATTY ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG LIVER LEVEL; DRUG METABOLISM; IMMUNE DEFICIENCY; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; KIDNEY; MALE; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ADIPOSE TISSUE; ANIMALS; ARACHIDONIC ACIDS; BRAIN; CARCINOMA; CORN OIL; DIETARY FATS; EICOSAPENTAENOIC ACID; EMULSIONS; ENTERAL NUTRITION; FATTY ACID DESATURASES; FATTY ACIDS, UNSATURATED; GAMMA-LINOLENIC ACID; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VISCERA;

EID: 0032799878     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Bégin ME, Ells G, Das UN and Horrobin DF: Differential killing of human carcinoma cells supplemented with n-3 and n-6 polyunsaturated fatty acids. J Nat Cancer Inst 77; 1053-1062, 1986.
2. Vartak S, McCaw R, Davis CS, Robbins MEC and Spector AA: γ-Linolenic acid (GLA) is cytotoxic to 36B10 malignant rat astrocytoma cells but not to "normal" rat astrocytes. Br J Cancer 77: 1612-1620,1998.
3. Sprecher H, Luthria D, Baykousheva SP and Mohammed BS: Pathways for the biosynthesis of polyunsaturated fatty acids. In: Gamma-linolenic acid metabolism and its roles in nutrition and medicine (Huang YS and Mills DE, eds). Champaign, Illinois, AOCS Press, 1996, pp 14-21.
4. Seegers JC, deKock M, Lottering ML, Grobler CJS, van Papendorp DH, Shou Y, Habbersett R and Lehnert BE: Effects of gamma-linolenic acid and arachidonic acid on cell cycle progression and apoptosis induction in normal and transformed cells. Prostaglandin Leukot Essent Fatty Acids 56: 271-280, 1997.
5. Lai PBS, Ross JA, Fearon KCH, Anderson JD and Carter DC: Cell cycle arrest and induction of apoptosis in pancreatic cancer cells exposed to eicosapentaenoic acid in vitro. Br J Cancer 74: 1375-1383, 1996.
6. Calviello G, Palozza P, Piccioni E, Maggiano N, Frattucci A, Franceschelli P and Bartoli GM: Dietary supplementation with eicosapentaenoic and docosahexaenoic acid inhibits growth of Morris hepatocarcinoma 3924A in rats: effects on proliferation and apoptosis. Int J Cancel 75; 699-705, 1998.
7. Jiang WG, Hiscox S, Bryce RP, Horrobin DF and Mansel RE: The effects of n-6 polyunsaturated fatty acids on the expression of nm-23 in human cancer cells. Br J Cancer 77: 731-738, 1998.
8. Jiang WG, Bryce RP, Horrobin DF and Mansel RE: Regulations of tight junction permeability and occludin expression by polyunsaturated fatty acids. Biochem. Biophys Res Commun: 244: 414-420, 1998.
9. Jiang WG, Bryce RP and Mansel RE: Gamma linolenic acid regulates gap junction communication in endothelial cells and their interaction with tumour cells. Prostaglandins Leukot Essent Fatty Acids 56: 307-316, 1997.
10. du Toit PJ, van Aswegen CH and du Plessis DJ: The effect of gamma-linolenic acid and eicosapentatenoic acid on urokinase activity. Prostaglandins Leukot Essent Fatty Acids 51: 121-124, 1994.
11. Jiang WG, Hiscox S, Hallett MB, Horrobin DF, Mansel RE and Puntis MCA: Regulation of the expression of E-cadherin on human cancer cells by γ-linolenic acid (GLA). Br J Cancer 71: 5043-5048, 1995.
12. Jiang WG, Hiscox S, Hallett MB, Scott C, Horrobin DF and Puntis MCA: Inhibition of hepatocyte growth factor-induced motility and in vitro invasion of human cancer cells by gamma-linolenic acid. Br J Cancer 71: 744-752, 1995.
13. Weber JM, Sircar S and Bégin ME: Greater sensitivity of human multidrug-resistant (mdr) cancer cells to polyunsaturated fatty acids than their non-mdr counterparts. J Nat Cancer Inst 86: 638-639, 1994.
14. Plumb JA, Luo W and Kerr DJ: Effect of polyunsaturated fatty acids on the drug sensitivity of human tumour cell lines resistant to either cisplatin or doxorubicin. Br J Cancer 67: 728-733, 1993.
15. Anderson KM, Seed T, Meng J, Ou D, Alrefai WA and Harris JE: Five-lipoxygenase inhibitors reduce PANC-1 survival: the mode of cell death and synergism of MK886 with gamma linolenic acid. Anticancer Res 18: 791-800, 1998.
16. Falconer JS, Ross JA, Fearon KCH, Hawkins RA, O'Riordian MG and Carter DC: Effect of eicosapentaenoic acid and other fatty acids on the growth in vitro of human pancreatic cell lines. Br J Cancer 69: 826-832, 1994.
17. Wigmore SJ, Fearon KCH, Maingay JP and Ross JA: Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci 92: 215-221, 1997.
18. Takeda S, Sim PG, Horrobin DF, Sanford T, Chisholm KA and Simmons V: Mechanism of lipid peroxidation in cancer cells in response to γ-linolenic acid (GLA) analyzed by GC-MS (I): conjugated dienes with peroxyl (o hydroperoxyl) groups and cell-killing effects. Anticancer Res 13: 193-200, 1993.
19. Bergelson LD: Some advances in the investigation of lipid substances. Chem Ind 597-604, 1974.
20. Vaver VA, Todria KG, Prokazova NV, Rozynov BV and Bergelson LD: Diol lipids. Acylated ethyleneglycol glycosides, a new type of natural glycolipid. Biochim Biophys Acta 486: 60-69, 1977.
21. Groth DP, Le Page GA, Heidelberger C and Stoesz PA: Metabolism of pyruvate in tumor homogenates. Cancer Res 12: 529-534, 1952.
22. Blom M, Andersson L, Carlsson A, Herslöf BG, Zhou L and Nilsson A: Pharmacokinetics, tissue distribution and metabolism of intravenously administered digalactosyldiacylglycerol and monogalactosyldiacylglycerol in the rat. J Liposome Res 6: 737-753, 1996.
23. Bergqvist MHJ, Herslöf BG: Isolation and purification of galactosyldiacylglycerols. Chromatogr 40: 129-133, 1995.
24. Horrobin D, Manku M, McMordie A, Knowles P, Redden P, Bradley P and Wakefield P: 1,3 propane diol derivatives as bioactive compounds. WO 96/34846, 1996.
25. Folch J, Lees M and Sloane-Stanley GA: A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226: 497-509, 1957.
26. de Antueno RJ, Cantrill RC, Huang YS, Ells GW, Elliot M and Horrobin DF: Metabolism of n-6 fatty acids by NIH-3T3 cells transfected with the ras oncogene. Mol Cell Biochem 139: 71 81, 1994.
27. de Antueno RJ, Cantrill RC, Huang Y-S, Raha SK, Elliot M and Horrobin DF: Effect of n-3 and n-6 fatty acids on hepatic microsomal lipid metabolism: a time course study. Mol Cell Biochem 118: 153-161,1992.
28. Chance WT, Ogle CK, Thomas I, Zhou L, Zhang X, Basanta M and Fischer JE: Immunostimulation following fish oil-based parenteral nutrition in tumor-bearing rats. Nutr Cancer 26: 303-312, 1996.
29. de Antueno R, Elliot M, Ells G, Quiroga P, Jenkins K and Horrobin D: In vivo and in vitro biotransformation of the lithium salt of gamma-linolenic acid by three human carcinomas. Br J Cancer 75: 1812-1818, 1997.
30. Liu D, Hu Q and Song YK: Liposomes clearance from blood: different animal species have different mechanisms. Biochim Biophys Acta 1240: 277-284, 1995.
31. Noda M, Tsukahara H and Ogata M: Enzymic hydrolysis of diol lipids by pancreatic lipase. Biochim Biophys Acta 529: 270-279, 1978.
32. Begin ME, Das UN, Ells G and Horrobin DF: Selective killing of human cancer cells by polyunsaturated fatty acids. Prostaglandins Leukot Med 19: 177-186, 1985.
33. Ligo M, Nakagawa T, Ishikawa C, Iwahori Y, Asamoto M, Yazawa K, Araki E and Tsuda H: Inhibitory effects of docosahexaenoic acid on colon carcinoma 26 metastasis to the lung. Br J Cancer 75: 650-655, 1997.
34. Jenski LJ, Zerouga M and Stillwell W: ω-3 Fatty acid-containing liposomes in cancer therapy. Proc Sci Exp Biol Med 210: 227-233, 1995.
35. de Bravo MG, de Antueno RJ, Toledo J, De Tomas ME, Mercuri OF, Quintans C: Effects of an eicosapentaenoic and docosahexaenoic acid concentrate on a human lung carcinoma grown in nude mice. Lipids 26: 866-870, 1991.
36. 2 synthesis in a human lung carcinoma. Biochem Int 19: 489-496, 1989.
37. Brouard C and Pascaud M: Effects of moderate dietary supplemenations with n-3 fatty acids on macrophage and lymphocyte phospholipids and macrophage eicosanoid synthesis in the rat. Biochim Biophys Acta 1047: 19-28, 1990.
38. Reich R and Martin GR: Identification of arachidonic acid pathways required for the invasive and metastatic activity of malignant tumor cells. Prostaglandins 51: 1-7, 1996.
39. Young MRI: Eicosanoids and the immunology of cancer. Cancer Metastasis Rev 13: 337-348, 1994.
40. Uotila P: Inhibition of prostaglandin E2 formation and histamine action in cancer immunotherapy. Cancer Immunol Immunother 37: 251-254, 1993.
41. Ondrey FG, Juhn SK and Adams GL: Inhibition of head and neck tumor cell growth with arachidonic acid metabolism inhibition. Laryngoscope 106: 129-134, 1996.